PHAGOCYTIC ACTIVITY AS A MARKER OF SYNUCLEINOPATHIC DISEASE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Nov 23, 2011
filing date -
Nov 24, 2010
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention provides methods of screening for agents useful in treating or prophylaxis of synucleinopathic disease, methods of diagnosis or prognosis of the same and methods of treatment and prophylaxis. The invention is based in part on the result that cells with phagocytic activity from subjects with synucleinopathic disease have increased levels of alpha synuclein and reduced phagocytic activity and that these processes can be reversed (i.e., synuclein levels decreased and phagocytic levels increased) by treatment with IL-4 among other agents. The increase in phagocytic activity is readily amenable to detection and provides a basis for a screening assay in which an agent is contacted with phagocytic cells and the effect of the agent on phagocytic activity is detected, which is an indicator that the agent has the ability to reduce alpha synuclein levels.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully